Liquidia Corp
LQDA Nasdaq Pharmaceutical Preparations Financials FY2019βFY2025
What Liquidia Corp does
No business description yet.
- Legal name
- Liquidia Corp
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 5, 2026
- Accession Β· CIK
- 0001104659-26-023804
0001819576
Revenue and margins
Liquidia Corp had $158M of revenue in fiscal 2025, up 1,031.2% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$40.0M in fiscal 2025, β25.3% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Liquidia Corp returned β to shareholders in fiscal 2025. The diluted share count rose 9.3%.
Balance sheet
Cash, debt and the ratios that show how comfortably Liquidia Corp can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $57.5M | $93.3M | $83.7M | $176M | $191M |
| Debt incl. finance leases | $11.1M | $20.2M | β | β | β |
| Debt / equity | 0.2x | 0.2x | β | β | β |
| Interest coverage | β44.4x | β16.6x | β11.7x | β8.3x | β2.1x |
| Current ratio | 8.4x | 11.3x | 4.8x | 4.4x | 2.0x |
| Quick ratio | 8.4x | 11.3x | 4.8x | 4.4x | 1.8x |
| Total assets | $93.7M | $129M | $118M | $230M | $328M |
| Total liabilities | $28.5M | $38.8M | $71.0M | $151M | $283M |
| Shareholders' equity | $65.3M | $90.4M | $47.3M | $79.4M | $44.7M |
| Net debt (β = net cash) | β$46.4M | β$73.1M | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 8 | 5 / 9 | 4 / 9 | 3 / 8 | 2 / 8 | 3 / 7 |
| Accruals ratio | 1.0% | β6.7% | β0.6% | β11.1% | β29.8% | β20.0% | β11.9% |
| Altman Z'' | β9.92 | β6.79 | β7.01 | β3.79 | β11.33 | β6.79 | β4.36 |
7 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $8.1M | $0.7M | $12.9M | $15.9M | $17.5M | $14.0M | $158M |
| Gross profit | β | $0.5M | $9.8M | $13.1M | $14.6M | $8.1M | β |
| Research and development | $40.5M | $32.2M | $20.5M | $19.4M | $43.2M | $47.8M | $39.3M |
| Operating income | β$46.8M | β$59.1M | β$33.8M | β$38.8M | β$73.4M | β$121M | β$51.4M |
| Interest expense | $1.4M | $0.9M | $0.8M | $2.3M | $6.3M | $14.7M | $24.2M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | β$47.6M | β$59.8M | β$34.6M | β$41.0M | β$78.5M | β$128M | β$68.9M |
| Diluted EPS | β$2.57 | β$1.76 | β$0.70 | β$0.67 | β$1.21 | β$1.63 | β$0.80 |
| Diluted shares | 0.02B | 0.03B | 0.05B | 0.06B | 0.06B | 0.08B | 0.09B |
| Cash flow | |||||||
| Cash from operations | β$48.3M | β$54.1M | β$34.0M | β$28.6M | β$41.6M | β$93.4M | β$35.7M |
| Capital expenditure | $1.9M | $0.8M | $0.1M | $0.6M | $1.3M | $4.9M | $4.3M |
| Free cash flow | β$50.1M | β$54.9M | β$34.1M | β$29.2M | β$42.9M | β$98.4M | β$40.0M |
| Depreciation and amortization | $2.6M | $3.1M | $5.6M | $3.6M | $2.2M | $2.2M | $1.5M |
| Stock-based compensation | $3.4M | $4.0M | $6.7M | $9.3M | $10.1M | $18.8M | $29.5M |
| Balance sheet | |||||||
| Cash and short-term investments | $55.8M | $65.3M | $57.5M | $93.3M | $83.7M | $176M | $191M |
| Total debt | $15.9M | $10.3M | $10.4M | $19.9M | β | β | β |
| Finance lease liabilities | β | $1.2M | $0.7M | $0.4M | $0.2M | $0.1M | β |
| Current assets | $56.4M | $66.1M | $61.3M | $99.8M | $89.9M | $185M | $273M |
| Current liabilities | $16.9M | $11.7M | $7.3M | $8.8M | $18.6M | $41.8M | $136M |
| Inventory | β | β | β | β | β | $0.2M | $23.8M |
| Property and equipment, net | $9.3M | $6.8M | $5.0M | $4.2M | $4.5M | $8.3M | $11.8M |
| Goodwill | $0.0M | $3.9M | $3.9M | $3.9M | $3.9M | $3.9M | $3.9M |
| Intangible assets | $0.0M | $5.5M | $4.4M | $3.7M | $3.4M | $3.2M | $3.0M |
| Total assets | $68.8M | $99.5M | $93.7M | $129M | $118M | $230M | $328M |
| Total liabilities | $33.9M | $28.4M | $28.5M | $38.8M | $71.0M | $151M | $283M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $34.9M | $71.1M | $65.3M | $90.4M | $47.3M | $79.4M | $44.7M |
| Margins | |||||||
| Gross margin | β | 67.9% | 76.5% | 82.1% | 83.5% | 58.0% | β |
| Operating margin | β580.1% | β7,989.3% | β263.0% | β243.3% | β419.6% | β866.6% | β32.5% |
| EBITDA margin | β548.3% | β7,566.2% | β219.3% | β220.4% | β407.2% | β850.9% | β31.5% |
| Net margin | β589.5% | β8,080.4% | β269.0% | β257.4% | β448.9% | β916.6% | β43.5% |
| FCF margin | β621.1% | β7,422.5% | β265.6% | β183.1% | β245.0% | β702.9% | β25.3% |
| Returns | |||||||
| Return on capital | β | β290.6% | β146.9% | β180.0% | β | β | β |
| Return on capital employed | β90.1% | β67.3% | β39.1% | β32.2% | β73.5% | β64.3% | β26.7% |
| Return on equity | β136.2% | β112.7% | β50.7% | β52.7% | β114.0% | β202.6% | β111.1% |
| Return on assets | β69.1% | β71.0% | β35.8% | β36.8% | β63.4% | β73.6% | β24.7% |
| Return on tangible equity | β136.2% | β96.9% | β60.7% | β49.5% | β196.5% | β177.4% | β181.9% |
| Growth | |||||||
| Revenue growth | β | β90.8% | 1,637.8% | 24.0% | 9.7% | β20.0% | 1,031.2% |
| Share count change | β | 83.4% | 46.6% | 22.7% | 6.6% | 21.1% | 9.3% |
| Financial health | |||||||
| Debt / equity | 0.5x | 0.1x | 0.2x | 0.2x | β | β | β |
| Interest coverage | β34.1x | β68.9x | β44.4x | β16.6x | β11.7x | β8.3x | β2.1x |
| Current ratio | 3.3x | 5.6x | 8.4x | 11.3x | 4.8x | 4.4x | 2.0x |
| Quick ratio | 3.3x | 5.6x | 8.4x | 11.3x | 4.8x | 4.4x | 1.8x |
| Capital allocation | |||||||
| Capex / revenue | 22.9% | 101.7% | 0.8% | 3.7% | 7.4% | 35.4% | 2.7% |
| Stock comp / revenue | 41.8% | 534.6% | 52.5% | 58.3% | 57.7% | 134.4% | 18.6% |
| Quality scores | |||||||
| Piotroski F-score | β | 4.0 | 5.0 | 4.0 | 3.0 | 2.0 | 3.0 |
| Altman Z'' | β9.9 | β6.8 | β7.0 | β3.8 | β11.3 | β6.8 | β4.4 |
| Accruals ratio | 1.0% | β6.7% | β0.6% | β11.1% | β29.8% | β20.0% | β11.9% |
Source: SEC EDGAR XBRL filings (CIK 0001819576). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.